MIAMI (PRWEB) June 04, 2014
GlobalStemCellsGroup.com, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced a new 16 CME online credit course for physicians. Working at their own pace from the privacy of home or office, physicians can learn how to implement regenerative medicine techniques in their own practices.
Taught by stem cell and regenerative medicine expert Kristin Comella, the online course provides didactic lectures on regenerative medicine and scientifically validated protocols. Lecture topics include:
Included in the online coursework are training videos, training booklets, detailed protocols and power point presentations with instructions and images for:
Medical professionals can also choose to combine the online coursework with one-on-one training with a regenerative medicine specialist.
For more information, visit the Global Stem Cells website,, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Kristin Comella:
Kristin Comella has more than 15 years’ experience in corporate entities with expertise in regenerative medicine. Comella has pioneered a variety of stem cell therapies including cord blood derived cells, bone marrow cells, muscle cells and adipose cells for use in many different applications. As Chief Scientific Officer for Bioheart, Inc., Comella has developed a wide range of regenerative products and techniques that have been successfully implemented into the clinic, and has led her team to earn the first ever FDA approval for clinical trials using a combined cell and gene therapy product.
Bioheart is a publicly traded company focusing on the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases. Since joining Bioheart in 2004, Comella has played a major role in managing the product development, manufacturing and quality systems of cellular products. Comella currently and actively serves on multiple boards in the stem cell arena. She joined forces with Global Stem Cells Group and its subsidiary Stem Cells Training in 2013 to design and lead intensive, hands-on stem cell training courses to industry professionals in the U.S. and abroad.